TARGETING INNATE IMMUNE REGULATORS TO REDUCE REJECTION IN VASCULARIZED COMPOSITE TISSUE TRANSPLANTS. NEW AWARD.

$999,030FY2020Department of the ArmyDOD

The General Hospital Corporation

Investigators